Home » TCT 2017: Edwards touts cost savings in Sapien 3
By Fink Densford
Edwards Lifesciences‘(NYSE:EW) yesterday released data from an economic study of its Sapien 3 transcatheter aortic heart valve in intermediate risk patients, touting lower total one-year costs with the valve compared to surgical aortic valve replacements.
The Irvine, Calif.-based company said the economic analysis was the first-of-its-kind to report on patients who are at an intermediate risk for open-heart surgery.
The trial examined results and costs in more than 2,000 patients from both the Partner II A trial and Sapien 3 intermediate risk trial, Edwards said. Results from the trial showed lower total one-year average costs with the Sapien 3 versus standard surgical interventions at $80,977 and $96,489, respectively.
Data also indicated lower average index hospitalization costs with the Sapien 3 versus surgery at $54,256 and $58,410 respectively. Contributing factors to the lower cost included reduced hospital stays, improved procedural efficiency, less repeat hospitalization and reduced rehabilitation time, Edwards said.
Edwards said that TAVR procedures with the Sapien 3 added 0.27 quality-adjusted life years per patient and savings of approximately $10,000 compared to surgery over a patient’s lifetime.
“Based on both clinical and economic considerations, these findings demonstrate that TAVR should be the preferred strategy for patients with severe aortic stenosis at intermediate surgical risk. Taken together with previous data demonstrating excellent clinical outcomes and significantly improved quality of life with TAVR, this latest study shows that TAVR with the Sapien 3 valve also provides important short and long-term economic advantages compared with surgery,”Dr. David Cohen of theUniversity of Missouri-Kansas City, who presented the study results, said in a press release.
Also included in the trial was an analysis of the Sapien XT valve compared to surgery, which found that TAVR procedures with the Sapien XT to be economically superior to open surgery. Improvements to quality-adjusted life expectancy and lower long-term costs than surgery were also noted, according to the study data.
Late last month, results from a new study comparing outcomes from TAVR procedures withBoston Scientific‘s (NYSE:BSX) Acurate Neo andEdwards Sapien 3 were found to be similar at 30 days.
In case you missed it
- Paragonix wins FDA clearance for next-gen lung preservation system
- GE HealthCare launches digital support tool for AFib
- Sanuwave to go public in $127.5M SPAC merger
- FDA review panel: Medtronic Symplicity Spyral RDN risks outweigh benefits
- First cancer patient treated with RefleXion biology-guided radiotherapy
- Integra Lifesciences hit with FDA warning letter over Boston facility
- Welldoc gets FDA nod for CGM-guided insulin bolus dosing software
- FDA clears software for Fresenius home hemodialysis system
- ReCor Medical wins FDA panel nod for its renal denervation system
- Untangling medtech CEO pay ratios: Exploring the industry’s corner office compensation dynamics
- Cydar Medical, Medtronic treat first patient in AI mapping collaboration
- Masimo initiates full U.S. launch of Stork smart home baby monitor
- Fast Five: Zimmer Biomet CEO leaves for another medtech company, Medtronic’s Q1 results
- Medtronic pleased with Diabetes progress as new CGM’s FDA review ‘is progressing’
- Magenta Medical completes enrollment in trial of tiny heart pump
From Medical Design & Outsourcing
- Risks of Medtronic Symplicity Spyral renal denervation (RDN) outweigh benefits: FDA review panel
An FDA review panel voted against recommending approval of Medtronic’s Symplicity Spyral renal denervation (RDN) therapy for hypertension under the proposed indications. The panel unanimously said the minimally invasive catheter system is safe, but was nearly split on efficacy. With six members voting that the benefits outweighed the risk, six voting the other way and… […]
- Vocxi Health and S3 Connected Health partner on lung cancer screening and monitoring
NEWS RELEASE: Vocxi Health and S3 Connected Health partner on lung cancer screening and monitoring Vocxi Health, a breath diagnostics company focused on accurate, non-invasive disease identification, has partnered with S3 Connected Health, the specialist digital health partner for life science companies, to bring game-changing technology to market to transform lung cancer detection and monitoring.… […]
- How Abbott designed the world’s first dual-chamber leadless pacemaker system
The lead engineer on Abbott’s AVEIR project explains how his team developed a first-of-its-kind wireless pacemaker system that communicates through blood. When Abbott’s AVEIR DR leadless pacemaker system became the first approved by the FDA for dual-chamber pacing this year, it expanded the benefits of leadless pacing to the majority of patients who need stimulation… […]
- ProMed Molded Products opens new development and innovation facility
NEWS RELEASE: ProMed Molded Products opens new development and innovation facility ProMed Molded Products, a contract manufacturer supporting applications in medical devices, drug-releasing combination devices, as well as specialized applications arenas for aerospace and defense and automotive, announces the opening of our new development facility in Plymouth, Minnesota. Located less than a mile from our… […]
- Device design and development tips for the future of stroke care
Simplicity and speed will be the most important innovations for medical devices that treat strokes in the years ahead. That’s according to Michael Gilvarry, GM of Johnson & Johnson MedTech’s Cerenovus Galway business. While he declined to divulge his neurovascular unit’s plans for future products, he offered advice for other device developers in a field… […]
- Medical Design & Outsourcing wins TABPI honors for B2B journalism
Medical Design & Outsourcing today won two Tabbie Awards for business-to-business journalism from Trade, Association and Business Publications International (TABPI). The publishing organization named Medical Design & Outsourcing‘s March 2022 edition as one of the top 25 issues in the category of best single issue. TABPI described that category as “the competition’s most comprehensive.” Award… […]
- Phillips-Medisize and Modular Medical partner on insulin delivery alternatives
NEWS RELEASE: Modular Medical Partners with Phillips-Medisize to Expand Insulin Delivery Alternatives Modular Medical, Inc. (Nasdaq:MODD), a development stage insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a collaboration under which Phillips-Medisize, a Molex company and a leader in the design, engineering and manufacturing… […]
- MassMEDIC announces 2023 MedTech Ignite accelerator cohort
The Massachusetts Medical Device Industry Council (MassMEDIC) today announced the 2023 cohort for its MedTech Ignite Program. MassMEDIC’s accelerator for medtech entrepreneurs features hybrid workshops, boot camps, conferences, networking opportunities and mentorships. The intensive three-month program runs from September to November 2023. The regional medtech association selected eight companies developing medical device, diagnostic and digital… […]
- The 10 largest orthopedic device companies in the world
Two of the world’s largest orthopedic device companies expect accelerated revenue growth this year. Strykerand Zimmer Biomet both upped their 2023 guidance during recent earnings calls,a sign that orthopedic procedures are bouncing back from the COVID-19 pandemic. GlobalData predicted earlier this year that the recovery will lift the ortho devices market to nearly $50 billion… […]
- Shunt device startup wants to break barriers in nitinol and heart sensing
Medical devices have yet to tap nitinol’s shape memory properties, but that’s just one breakthrough Adona Medical hopes to achieve with its adjustable, bi-atrial-sensing heart shunt. Adona Medical co-founder and CEO Brian Fahey’s presentation on his shunt device startup’s aspirations elicited palpable interest from the cardiologists in the room at CSI Frankfurt. “You plan to… […]
- Medical nitinol processing: How NiTi is turned into wire, tubes and sheets for medical devices
Medical nitinol processing transforms raw nickel-titanium alloy into wire, coils, tubes and sheets for medical and dental device manufacturers. We previously covered nitinol’s journey from the earth’s crust through high-temperature melting crucibles and forging operations to create nitinol ingots and then smaller, more workable shapes such as rods and plates. But turning those into wires,… […]